Robot Sidekick for Nose-Throat Ops Gets FDA Fast-Track
Published Date: 9/10/2026
Rule
Summary
The FDA is officially classifying a new powered surgical device for ear, nose, and throat (ENT) surgeries as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the device safer and easier to get to patients, starting September 10, 2026, with the classification effective retroactively from July 19, 2023. Doctors, hospitals, and device makers will benefit from clearer rules and faster access to this innovative tool without extra costs.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Easier Patient Access to ENT Robotics
FDA placed the cooperative powered surgical assist device for ear, nose, and throat (ENT) surgery into Class II with special controls, and says this will enhance patient access to beneficial innovative devices by reducing regulatory burdens. The final order is effective September 10, 2026, and the classification was applicable on July 19, 2023.
Subject to 510(k) Premarket Notification
FDA says cooperative powered surgical assist devices for ENT surgery are subject to premarket notification requirements under section 510(k). If you make this device, you must submit a 510(k) to FDA before marketing the device unless FDA later exempts the device type.
Creates Predicate for Future Devices
FDA says a device classified into Class II via the De Novo process can serve as a predicate for future devices, meaning other sponsors can use the less burdensome 510(k) process rather than a De Novo request or premarket approval. This can reduce regulatory burden for future device makers developing similar ENT surgical assist devices.
Required Special Controls and Testing
FDA sets special controls for these devices that manufacturers must meet, including simulated-use testing in an anatomically relevant model, compatibility testing, human factors/usability evaluation, software verification and hazard analysis, electromagnetic/electrical/thermal safety testing, sterilization and shelf-life testing, biocompatibility, and specific labeling (e.g., compatible instruments and training statements).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-18428, Medical Devices; Gastroenterology-Urology Devices; Classification of the Implanted Tibial Electrical Urinary Continence Device
The Food and Drug Administration (FDA) is classifying the implanted tibial electrical urinary continence device into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the implanted tibial electrical urinary continence device. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Next: 2026-18430, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Anti-Tumor Necrosis Factor Alpha Monoclonal Antibody Test System for Inflammatory Bowel Disease
The FDA is officially putting the anti-tumor necrosis factor alpha monoclonal antibody test for inflammatory bowel disease into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this important test faster and keeps it safe and effective. The new classification started back in September 2023 and is now fully in effect as of September 2026.